Oscar Health's membership surge masks persistent profitability risks

What happened

Oscar Health reported a 46% year-over-year jump in membership to 2.96 million, reflecting continued scale gains in the ACA Marketplace. However, the increase is accompanied by seasonal enrollment dynamics and elevated medical utilization that cloud the path to sustainable profitability. The company's latest filings show a net risk-adjustment payable of $3.974 billion after a $1.443 billion build in Q1 2026, signaling a significant earnings drag. Management's full-year medical loss ratio guidance of 82.4%-83.4% remains well above Q1's 70.5%, indicating that recent favorable reserve development may not repeat. The membership figure also represents a decline from the post-open-enrollment peak of 3.17 million, consistent with prior disclosures about the impact of expiring enhanced premium subsidies.

Implication

The article corroborates the master report's view that Oscar's profitability is fragile, with membership growth masking underlying utilization and regulatory transfer risks. The build in risk-adjustment payable indicates that Oscar is transferring a significant portion of premiums to other insurers, which could erode capital if not reversed. The company's own guidance for MLR normalization suggests that Q1's strong earnings were partly driven by favorable reserve development rather than improved underwriting. Additionally, the membership figure of 2.96 million, while up year-over-year, is below the Q1 peak, confirming that enhanced subsidy expiration is causing attrition. Overall, the thesis remains bearish, and investors should wait for evidence of stabilizing risk-adjustment accruals and MLR before reconsidering the name.

Thesis delta

The news does not materially alter the master thesis; it confirms strong membership growth but highlights the same profitability concerns related to medical utilization and seasonal enrollment. The core risks identified in the master report—elevated risk-adjustment payable and expected MLR reversion—remain unchanged. Therefore, the thesis remains a 'potential sell' with no shift in conviction.